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Cancer vaccine which induces cytotoxic T lymphocyte
targeting tumor associated antigens is one of major stream
in cancer immunotherapy. Many cancer immunotherapy
programs are in the clinical development all over the
world and also the identification of biomarker for pharma-
codynamics and patient selection should be considered.
Enzyme-linked immunospot (ELISPOT) assay is one
useful method to detect antigen specific T cell response as
an immunomonitoring. However, the standardization of
the ELISPOT assay has not yet been established, and it has
strongly been mandatory to detect accurate and objective
immune response for clinical development of cancer
vaccine. To overcome this problem, we have developed an
automated immunomonitoring system, which performs
cell culture processes including cell recovery, seeding and
detection of the particular cells for ELISPOT assay. This
automated cell culture system might be useful to control
the quality of assays with cell culture and high-throughput
outcomes. In this presentation, we show the concept and
the characteristic of the automated immunomonitoring
system.
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